AR084541A1 - PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA - Google Patents

PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA

Info

Publication number
AR084541A1
AR084541A1 ARP110104884A ARP110104884A AR084541A1 AR 084541 A1 AR084541 A1 AR 084541A1 AR P110104884 A ARP110104884 A AR P110104884A AR P110104884 A ARP110104884 A AR P110104884A AR 084541 A1 AR084541 A1 AR 084541A1
Authority
AR
Argentina
Prior art keywords
robo1
hepatocarcinoma
treatment
fusion protein
protein
Prior art date
Application number
ARP110104884A
Other languages
English (en)
Inventor
Genevieve Gueguen-Dorbes
Frederique Dol-Gleizes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45440542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR1061163A external-priority patent/FR2969617A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR084541A1 publication Critical patent/AR084541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere al uso de una proteína Robo1-Fc para tratar el cáncer, en particular hepatocarcinomas. Proteína recombinante que comprende el dominio extracelular de la proteína Robo1.
ARP110104884A 2010-12-23 2011-12-22 PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA AR084541A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1061163A FR2969617A1 (fr) 2010-12-23 2010-12-23 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs.
EP11306336 2011-10-14

Publications (1)

Publication Number Publication Date
AR084541A1 true AR084541A1 (es) 2013-05-22

Family

ID=45440542

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104884A AR084541A1 (es) 2010-12-23 2011-12-22 PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA

Country Status (18)

Country Link
US (1) US20130273049A1 (es)
EP (1) EP2655408B1 (es)
JP (1) JP2014507395A (es)
KR (1) KR20130132880A (es)
CN (1) CN103703021A (es)
AR (1) AR084541A1 (es)
AU (1) AU2011347250B2 (es)
CA (1) CA2820781A1 (es)
CL (1) CL2013001861A1 (es)
CO (1) CO6741197A2 (es)
EA (1) EA201390955A1 (es)
MA (1) MA34827B1 (es)
MX (1) MX2013007421A (es)
PH (1) PH12013501205A1 (es)
SG (1) SG191060A1 (es)
UY (1) UY33833A (es)
WO (1) WO2012085178A1 (es)
ZA (1) ZA201305266B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
SG11201403746SA (en) 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104873986A (zh) * 2015-03-23 2015-09-02 广东药学院 一种治疗肝脏纤维化的siRNA及其应用
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
KR20200016292A (ko) 2017-06-02 2020-02-14 화이자 인코포레이티드 재조합 robo2 단백질, 조성물, 방법 및 그의 용도
WO2020175931A1 (ko) * 2019-02-27 2020-09-03 주식회사 대웅제약 알부민이 결합된, slit3 단백질의 lrrd2를 포함하는 근육 질환 예방 또는 치료용 조성물
TW202511284A (zh) * 2023-09-14 2025-03-16 大陸商北京拓界生物醫藥科技有限公司 包含robo結構域的蛋白及其醫藥用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE69816467T2 (de) * 1997-10-20 2004-04-15 The Regents Of The University Of California, Oakland Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
ES2431040T3 (es) * 2002-03-08 2013-11-22 Shanghai Institutes For Biological Sciences, Cas Detección y modulación de la angiogénesis mediada por Slit y Roundabout (Robo), y sus usos
KR101300544B1 (ko) * 2004-03-31 2013-09-02 히로유키 아브라타니 항ｒｏｂｏ1항체를 이용하는 암의 진단 및 치료
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
MX2010002716A (es) * 2007-09-14 2010-07-05 Scil Technology Gmbh Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用

Also Published As

Publication number Publication date
ZA201305266B (en) 2014-09-25
US20130273049A1 (en) 2013-10-17
EP2655408A1 (en) 2013-10-30
WO2012085178A1 (en) 2012-06-28
SG191060A1 (en) 2013-07-31
EP2655408B1 (en) 2016-07-06
PH12013501205A1 (en) 2013-07-29
MX2013007421A (es) 2014-02-03
CO6741197A2 (es) 2013-08-30
CL2013001861A1 (es) 2014-04-04
AU2011347250A1 (en) 2013-05-02
KR20130132880A (ko) 2013-12-05
UY33833A (es) 2012-07-31
EA201390955A1 (ru) 2013-11-29
CA2820781A1 (en) 2012-06-28
CN103703021A (zh) 2014-04-02
AU2011347250B2 (en) 2015-06-04
MA34827B1 (fr) 2014-01-02
JP2014507395A (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
AR084541A1 (es) PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
CR20110553A (es) Terapia complementaria contra el cáncer
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
EA201171367A1 (ru) Винилиндазолильные соединения
CL2012003385A1 (es) Tratamiento para la incontinencia.
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
UY34885A (es) Proteínas de unión anti-mesotelina
CL2009001263S1 (es) Maquina de afeitar.
CR20110560A (es) Métodos de tratamiento para tumores sólidos
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
EA201400178A1 (ru) Лечение рака молочной железы
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CL2009001624S1 (es) Maquina para preparar bebidas.
MX385575B (es) Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis.
EP2721520A4 (en) SELECTION DISPLAY BETWEEN RECEIVED FILES AND SOURCE FILES
MX2019009539A (es) Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
CL2009001363S1 (es) Pieza para maquina de afeitar.
BR112012015597A2 (pt) peptídeos de somatotropina suínos modificados e seus usos
MX374220B (es) Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal